The Search for Genomic Biomarkers of Response to Immunotherapy in Ovarian Cancer

Summary

Immune checkpoint blockade has been ineffective in ovarian cancer, and there is an ongoing effort to identify biomarkers of therapeutic benefit. Despite promising preclinical data, a substudy of the IMagyn050 trial found that patients with homologous recombination deficient tumors did not have improved progression-free survival with the addition of the PD-L1 inhibitor atezolizumab.

See related article by Landen et al., p. 1698